Submit Content
Get the latest delivered to your inbox
Privacy Policy

Accelerating the Next Generation of Climate Policy and Protecting Human Health

Published 09-17-20

Submitted by Biogen

Climate change is a public health crisis that impacts everyone, but especially vulnerable populations. Massachusetts is on a path towards net-zero carbon emissions by 2050 but more needs to be done, and fast. COVID has shown the injustice of the pandemic and we know the equity gaps of the climate crisis. With the support of leading institutions like MIT and Harvard, and forward-looking companies like Biogen, Massachusetts can be effect real actions in the state and well-beyond and become a model for addressing climate change, with clear considerations to health for all populations.

Featured speakers:

  • Charlie Baker, Governor | The Commonwealth of Massachusetts
  • Linda Henry, Managing Director | Boston Globe Media
  • Michel Vounatsos, CEO | Biogen
  • Eugenia Gibbons, Director | Healthcare Without Harm
  • Elizabeth Turnbull Henry, President, CEO | Environmental League of Massachusetts
  • Mindy S. Lubber, CEO & President | Ceres
  • Dr. Aaron Bernstein, C-Change | Harvard
  • Kate Walsh, President and CEO | Boston Medical Center
  • Kathleen A. Theoharides, Secretary | Executive Office of Energy and Environmental Affairs

Monday, September 21,  2020 10:00am — 11:00am

REGISTER NOW

Biogen Logo

Biogen

Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain. We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

More from Biogen

Join today and get the latest delivered to your inbox